Trellus Management Company’s Iovance Biotherapeutics IOVA Stock Holding History

Trellus Management Company’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-50,000	Closed	-$254K	–	68
2016 Q1	$254K	Sell	50,000 -10,539	-17%	-$57.7K	0.44%	48
2015 Q4	$467K	Hold	60,539	–	–	0.69%	47
2015 Q3	$349K	Buy	60,539 +22,039	+57%	+$172K	0.51%	55
2015 Q2	$353K	Buy	+38,500	New	+$430K	0.4%	65

Other funds holding IOVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Trellus Management Company's IOVA Position: Q2 2016 in Review

Trellus Management Company sold out of Iovance Biotherapeutics (IOVA) in Q2 2016, closing a stake of 50,000 shares — an estimated $254K sold.

Trellus Management Company first reported a position in IOVA in Q2 2015 and held it in 4 quarters. The position peaked at $467K in Q4 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q2 2016.

Trellus Management Company reported no remaining Iovance Biotherapeutics position as of Q2 2016 after selling out during the quarter.
Trellus Management Company sold 50,000 Iovance Biotherapeutics shares in Q2 2016, an estimated $254K.
Trellus Management Company first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 4 quarters.
Trellus Management Company's Iovance Biotherapeutics position peaked at $467K in Q4 2015.
82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2016.

Based on Trellus Management Company's 13F filing for Q2 2016, filed 18 Jul 2016.